Anticancer activity of chlorhexidine and cranberry extract: an in-vitro study.

Q3 Pharmacology, Toxicology and Pharmaceutics

Journal of Experimental Therapeutics and Oncology Pub Date : 2018-05-01

Mahesh R Khairnar, Umesh Wadgave, Harish Jadhav, Rahul Naik

{"title":"Anticancer activity of chlorhexidine and cranberry extract: an in-vitro study.","authors":"Mahesh R Khairnar, Umesh Wadgave, Harish Jadhav, Rahul Naik","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: Oral cancer is considered to be a global pandemic. The study was conducted to assess the anti-cancer activities of Chlorhexidine (CHX) and Cranberry against oral cancer cell lines.Material and methods: Anticancer activity of CHX and Cranberry extract (CE) was assessed against AW13516 (poorly to moderately differentiated squamous cell carcinoma of tongue) and KB (Nasopharyngeal carcinoma) using Sulforhodamine B (SRB) assay at the Advanced Centre for Treatment Research and Education in Cancer (ACTREC) Mumbai, India. Three dose related parameters GI50, TGI and LC50 were calculated for each drug.Results: CE (80µg/ml) showed no anti-cancer property against AW13516 cell line; however it showed 70.6% growth inhibition against KB cell line. CHX demonstrated 80.15% & 95.7% of growth inhibition against AW13516 & KB cell line respectively. Both the drugs were less potential than positive control drug Adriamycin, as reflected by their GI50, TGI and LC50 values.Conclusion: CHX exhibited better anti-cancer properties than CE for both the oral cancer cell lines.","PeriodicalId":45335,"journal":{"name":"Journal of Experimental Therapeutics and Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Therapeutics and Oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Oral cancer is considered to be a global pandemic. The study was conducted to assess the anti-cancer activities of Chlorhexidine (CHX) and Cranberry against oral cancer cell lines.

Material and methods: Anticancer activity of CHX and Cranberry extract (CE) was assessed against AW13516 (poorly to moderately differentiated squamous cell carcinoma of tongue) and KB (Nasopharyngeal carcinoma) using Sulforhodamine B (SRB) assay at the Advanced Centre for Treatment Research and Education in Cancer (ACTREC) Mumbai, India. Three dose related parameters GI50, TGI and LC50 were calculated for each drug.

Results: CE (80µg/ml) showed no anti-cancer property against AW13516 cell line; however it showed 70.6% growth inhibition against KB cell line. CHX demonstrated 80.15% & 95.7% of growth inhibition against AW13516 & KB cell line respectively. Both the drugs were less potential than positive control drug Adriamycin, as reflected by their GI50, TGI and LC50 values.

Conclusion: CHX exhibited better anti-cancer properties than CE for both the oral cancer cell lines.

本刊更多论文

氯己定和蔓越莓提取物的抗癌活性:体外研究。

口腔癌被认为是一种全球性流行病。研究了氯己定(CHX)和蔓越莓对口腔癌细胞株的抗癌作用。材料和方法:在印度孟买的高级癌症治疗研究和教育中心(ACTREC)，采用硫代氨基B (SRB)法评估CHX和蔓越莓提取物(CE)对AW13516(低分化至中分化鳞状细胞癌)和KB(鼻咽癌)的抗癌活性。计算每种药物的三个剂量相关参数GI50、TGI和LC50。结果:CE(80µg/ml)对AW13516细胞株无抗癌作用;对KB细胞株的生长抑制率为70.6%。CHX对AW13516和KB细胞系的生长抑制作用分别为80.15%和95.7%。两种药物的GI50、TGI和LC50值均低于阳性对照药物阿霉素。结论:CHX对两种口腔癌细胞系的抗癌作用均优于CE。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Experimental Therapeutics and Oncology ONCOLOGY-

自引率

0.00%

发文量